Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding.
about
Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal diseaseDefining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigenProtein Crystallography in Vaccine Research and DevelopmentMonoclonal antibodies to meningococcal factor H binding protein with overlapping epitopes and discordant functional activityEmerging experience with meningococcal serogroup B protein vaccines.Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH bindingThe effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein.Meningococcal disease and the complement system.Heterogeneity in rhesus macaque complement factor H binding to meningococcal factor H binding protein (FHbp) informs selection of primates to assess immunogenicity of FHbp-based vaccines.Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa.A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity.Neisseria gonorrhoeae NspA induces specific bactericidal and opsonic antibodies in miceA Mutant Library Approach to Identify Improved Meningococcal Factor H Binding Protein Vaccine Antigens.Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein.Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidisFunctional Analysis of the Human Antibody Response to Meningococcal Factor H Binding ProteinA broadly cross-reactive monoclonal antibody against an epitope on the n-terminus of meningococcal fHbp.The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease.The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococciBinding of Complement Factor H (FH) Decreases Protective Anti-FH Binding Protein Antibody Responses of Infant Rhesus Macaques Immunized With a Meningococcal Serogroup B Vaccine.The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens.Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H.Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C VaccineEffect of complement Factor H on anti-FHbp serum bactericidal antibody responses of infant rhesus macaques boosted with a licensed meningococcal serogroup B vaccineImpaired Immunogenicity of Meningococcal Neisserial Surface Protein A in Human Complement Factor H Transgenic Mice.A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccineImportance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccinesfH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations.Human IgG1, IgG3, and IgG3 Hinge-Truncated Mutants Show Different Protection Capabilities against Meningococci Depending on the Target Antigen and Epitope Specificity.Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice.Preclinical evaluation of MenB vaccines: prerequisites for clinical development.Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen.Serum Bactericidal Antibody Responses of Students Immunized With a Meningococcal Serogroup B Vaccine in Response to an Outbreak on a University Campus.Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C.Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes.Molecular characterization of two sub-family specific monoclonal antibodies to meningococcal Factor H binding protein.Spontaneous point mutations in the capsule synthesis locus leading to structural and functional changes of the capsule in serogroup A meningococcal populations
P2860
Q26995760-FEBB3B4B-8B76-4323-A5BE-E2D629E565A2Q27676318-F433AE6F-D656-4749-A2A6-371FD8DBFCA7Q28087528-5266BB24-B5F7-4AF7-AF27-FA07262CD38AQ28730934-8259256B-8EE5-4038-9945-3C5C00444E65Q30234958-C3AD5A1A-0AE0-4F6D-B9A4-BB995CC9C5C7Q30248749-D4C4C819-D116-4548-93C3-3F329ED91C5FQ34237895-D80E7B54-916F-4B0E-A71E-34BA3A1171BBQ34270429-1791F175-4D85-4848-944C-61D316AD4F9EQ34376170-4064212B-56F4-4F6C-A8CC-9C9F3717E045Q34592926-103B41E0-1826-4071-83EF-8D421B3D066EQ34785389-FDDF6E52-C7FA-4953-9FA1-C314F255ABCCQ35181636-51514623-BF66-4C85-9429-BCE1C27676E5Q35187629-424671F9-2680-43FA-B367-B8934513CA6AQ35530224-C750921D-4D3B-4C59-9DDB-B98D95F9053FQ35658277-DDB055C3-B55A-450D-AFEB-3AF59D8D0E6AQ35665404-E9EA34D9-5183-4040-87B7-4EE20932C04CQ35689526-8C2F810B-F7D6-4F01-A761-8453838BD682Q35777766-EA2A1BBD-2DF6-473E-8C94-BBD13D5A2D6EQ35857593-1812B367-10D6-496B-A561-B23F52ECE5B2Q35886792-BD6DFBA4-54DA-4B1A-AEF2-22D9CEF82BBBQ35936064-D2F06A33-8801-4D2C-9ACA-73648499A4B0Q35965207-E08BB757-1DF7-4B2E-A431-EB287978196FQ35989852-C8F77113-57C9-4B83-A347-1FD8CA0CAD1CQ36211092-C59EE61C-0E96-4F59-8CEA-89C6298616BBQ36316767-B95FAFDC-8B15-4782-A68F-7D03E77D16D4Q36385023-68BEEE69-219F-415A-9281-8658D4405BFDQ36513433-6D477EC0-EE50-4B58-B497-6076067D8B91Q36521563-A7FDAE9E-C3EF-4BFA-B89B-90CD2BF1EBA9Q37037083-CB18714B-ACCF-4028-8B56-563114027267Q37130358-794CC422-EF0B-4C97-9E9E-8471AE65E5D2Q37163679-0038AE9A-2347-4ECE-81F9-18CE5BE1078BQ37401146-D715D07C-0957-47C7-B260-AC986EF3E1C5Q38068953-2B3AE777-246E-40A6-8865-C571EBB6C9AFQ38363907-D2242CE7-B0F2-4ABE-B91E-5F5AB2D57EC6Q40172533-998C92CD-1097-4621-8887-06B4ED60455EQ40178578-2D2ED31B-119D-4839-B82B-25AD8DF08580Q50922458-EC8361E9-4DE2-477D-95B5-47601FBFB962Q52682421-19BC9CEE-0F50-4B41-A6E1-ECF558288D9BQ55266742-A4F9304F-76FB-4A66-86E9-7F8BF8B0FB12Q58806131-4D4CE734-C581-4801-BECF-2BAB89ED9E19
P2860
Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Complement-mediated bactericid ...... pon blocking factor H binding.
@ast
Complement-mediated bactericid ...... pon blocking factor H binding.
@en
type
label
Complement-mediated bactericid ...... pon blocking factor H binding.
@ast
Complement-mediated bactericid ...... pon blocking factor H binding.
@en
prefLabel
Complement-mediated bactericid ...... pon blocking factor H binding.
@ast
Complement-mediated bactericid ...... pon blocking factor H binding.
@en
P2093
P2860
P356
P1476
Complement-mediated bactericid ...... pon blocking factor H binding.
@en
P2093
Dan M Granoff
Donald C Reason
Serena Giuntini
P2860
P304
P356
10.1128/IAI.05182-11
P407
P577
2011-06-27T00:00:00Z